This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
TFX vs. EW: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
TFX vs. EW: Which Stock Is the Better Value Option?
Is Teleflex Stock a Smart Option for Your Portfolio Right Now?
by Zacks Equity Research
TFX instils optimism with its robust performance in the Interventional category and potential in Asia.
Veracyte (VCYT) Up 9.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
TFX or PEN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
TFX vs. PEN: Which Stock Is the Better Value Option?
Teleflex's (TFX) Titan SGS Stapler Showcases Positive Outcomes
by Zacks Equity Research
Teleflex (TFX) publishes an analysis of clinical data showcasing the Titan SGS Stapler's enhanced clinical outcomes and significant efficiency benefits.
TFX or EW: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
TFX vs. EW: Which Stock Is the Better Value Option?
Align Technology (ALGN) Encounters Low ASP, FX Headwinds
by Zacks Equity Research
Align Technology's (ALGN) Clear Aligner ASP is facing a significant impact of unfavorable foreign exchange across multiple currencies.
Is Phibro (PAHC) Stock Worth Retaining in Your Portfolio Now?
by Zacks Equity Research
Phibro's (PAHC) Animal Health business, supported by the flourishing Vaccine product line, drives optimism for future growth. However, macroeconomic impacts are a concern.
TFX or EW: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
TFX vs. EW: Which Stock Is the Better Value Option?
Why Teleflex (TFX) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Teleflex (TFX) Tops Q2 Earnings Estimates, Raises 2024 Outlook
by Zacks Equity Research
Teleflex's (TFX) diversified portfolio and global footprint have driven durable growth in the second quarter of 2024.
Compared to Estimates, Teleflex (TFX) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Teleflex (TFX) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Teleflex (TFX) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 2.70% and 1.79%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for These 4 MedTech Stocks in Q2 Earnings?
by Urmimala Biswas
Here is a sneak peek into how four MedTech companies, LH, BIO, TFX and BRKR, are expected to fare in their second-quarter results, slated to be released tomorrow.
What Analyst Projections for Key Metrics Reveal About Teleflex (TFX) Q2 Earnings
by Zacks Equity Research
Get a deeper insight into the potential performance of Teleflex (TFX) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Earnings Preview: 908 Devices Inc. (MASS) Q2 Earnings Expected to Decline
by Zacks Equity Research
908 Devices (MASS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Teleflex (TFX) Q2 Earnings Expected to Decline
by Zacks Equity Research
Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What Makes Teleflex (TFX) a New Buy Stock
by Zacks Equity Research
Teleflex (TFX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
TFX vs. SONVY: Which Stock Is the Better Value Option?
by Zacks Equity Research
TFX vs. SONVY: Which Stock Is the Better Value Option?
Is it Wise to Hold Teleflex (TFX) Stock in Your Portfolio Now?
by Zacks Equity Research
Teleflex (TFX) holds strong momentum in the Interventional arm and a favorable solvency. Yet, macroeconomic impacts and competitive environment trigger concerns.
Glaukos (GKOS) Stock Jumps 3.7%: Will It Continue to Soar?
by Zacks Equity Research
Glaukos (GKOS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Teleflex's (TFX) Urolift Drives Market Share, Macro Woes Stay
by Zacks Equity Research
The commercialization of Teleflex's (TFX) UroLift in Japan has been a significant step toward making this therapy more broadly available to men suffering from BPH.